Summary:

Multi-site implementation science survey evaluating frontline clinician and support staff perceptions of using blood-based biomarkers (BBMs) to confirm amyloid pathology in routine Alzheimer's disease care across diverse US clinical settings. Participants reported high acceptability, appropriateness, and feasibility of BBM implementation, with strong support for their integration into existing clinical workflows and use in patients with intermediate or high suspicion of Alzheimer's disease.  

Keywords:

• Blood-based biomarkers (BBMs)
• Alzheimer's disease (AD)
• Amyloid pathology
• Confirmatory biomarkers
• Biomarker implementation
• Alzheimer's diagnosis
• Cognitive symptoms
• Mild cognitive impairment (MCI)
• Amyloid testing
• Clinical practice guidelines
• Implementation science
• Real-world evidence (RWE)
• Acceptability
• Appropriateness
• Feasibility
• Implementation outcomes
• Frontline perspectives
• Healthcare provider perceptions
• Workflow integration
• Clinical adoption
• Organizational readiness
• Implementation barriers and facilitators
• Practice transformation